(Q40692884)

22 September 2017

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar (English)

1 reference

22 September 2017

0 references

visceral leishmaniasis

1 reference

inferred from title

sodium stibogluconate

1 reference

M Mishra

1

1 reference

22 September 2017

U K Biswas

series ordinal

2

1 reference

22 September 2017

A M Jha

series ordinal

3

1 reference

22 September 2017

A B Khan

series ordinal

4

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 December 1994

1 reference

22 September 2017

1 reference

22 September 2017

344

1 reference

22 September 2017

8937

1 reference

22 September 2017

1599-1600

1 reference

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990406-5

7 January 2021

Liposomal amphotericin B in the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990406-5

7 January 2021

TREATMENT OF KALA-AZAR WITH AMPHOTERICIN B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990406-5

7 January 2021

Amphotericin B for second-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990406-5

7 January 2021

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990406-5

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2990406-5

7 January 2021

10.1016/S0140-6736(94)90406-5

Identifiers

DOI

1 reference

22 September 2017

1 reference